That has been my thinking for some time now. Prurisol is the most likely candidate for partnership because it is the easiest to value based on the Phase 2 results. I like that the bashers will have no idea if it works or not until unblinded results are released. There is even a slight possibility that data could be released concurrently with a partnership deal.